Kodiak Sciences Inc.
Financials
Valuation Metrics
Kodiak Sciences Inc.'s Market Cap is $2.05B. At end of 2025 it was $1.49B. Ranked #2011 of 3,121 in US market (top 64%), #766 of 1,463 on NASDAQ (top 52%), #137 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.05B | US#2,011/3,121 Sec#137/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-242M | US—/3,121 Sec—/266 |
| Total Assets | $257M | US#2,951/3,121 Sec#224/266 |
| Net Assets | $61M | US#2,850/3,121 Sec#221/266 |
| Employees | 141 | US#2,565/3,121 Sec#154/266 |
| Value | ||
| P/B | 33.50x | US#2,861/3,121 Sec#231/266 |
| FCF Yield | -7.81% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -94.23% | US#3,058/3,121 Sec#253/266 |
| Financial Health | ||
| Debt Ratio | 320.34% | US#2,157/3,121 Sec#216/266 |
| Total Debt | $96M | US#2,455/3,121 Sec#122/266 |
| FCF | $-160M | US#2,735/3,121 Sec#187/266 |
| Cash | $126M | US#2,064/3,121 Sec#150/266 |
| Current Ratio | 2.49x | US#981/3,121 Sec#204/266 |
| Performance | ||
| 1Y Return | 232.42% | US#39/3,121 Sec#18/266 |
| 1M Return | -18.37% | US#2,952/3,121 Sec#237/266 |
| From 52W High | -31.63% | US#2,127/3,121 Sec#168/266 |
| 1Y MDD | -36.24% | US#1,817/3,121 Sec#125/266 |
| Trading | ||
| Volume | 1,511,628 shares | US#1,576/3,121 Sec#173/266 |
| Trading Value | $49M | US#1,689/3,121 Sec#132/266 |
| Per Share | ||
| EPS | $-3.87 | US—/3,121 Sec—/266 |
| BPS | $0.98 | US#2,703/3,121 Sec#206/266 |
Company Info
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.